Generative Artificial Intelligence (AI) In Drug Discovery Market Global Report 2026

The generative artificial intelligence (AI) in drug discovery market size has grown exponentially in recent years. It will grow from $0.25 billion in 2025 to $0.33 billion in 2026 at a compound annual growth rate (CAGR) of 31.2%. The growth during the historic period can be attributed to high drug development costs, advancements in computational chemistry, increasing availability of biological datasets, adoption of machine learning tools, and rising pharmaceutical R&D investment.

The generative artificial intelligence (AI) in drug discovery market size is expected to see exponential growth in the next few years. It will grow to $0.87 billion in 2030 at a compound annual growth rate (CAGR) of 27.2%. The growth during the forecast period can be attributed to the integration of generative models into drug discovery pipelines, increasing demand for faster drug discovery processes, expansion of biologics optimization, growing collaboration between AI companies and pharmaceutical firms, and reduced time-to-market. Key trends during the forecast period include rising adoption of AI-driven molecule generation, increased use of deep learning in drug design, expansion of small molecule discovery applications, greater integration of AI into lead optimization, and accelerated early-stage drug development.

The rising number of clinical trials is expected to propel the growth of generative AI in the drug discovery market. Clinical trials involve human volunteers to evaluate the safety and effectiveness of new medical treatments or procedures and generate scientific evidence regarding their suitability for human use. The increasing number of clinical trials is primarily driven by advancements in medical research, the growing disease burden, regulatory changes, globalization of clinical research, increased patient advocacy and awareness, industry competition, technological advancements, and greater funding opportunities. Clinical trial data provides valuable inputs for generative AI models, accelerating drug discovery by predicting molecular interactions and designing new compounds. This combination supports personalized medicine, optimizes treatment effectiveness, improves patient outcomes, and transforms the pharmaceutical landscape. For instance, in January 2025, according to Pharmaceutical Technology, a UK-based business news and media company, 3,213 trials were planned to start in 2025, including 823 Phase I trials and 1,102 Phase II trials. Similar to 2024, oncology was expected to remain the leading therapeutic area, accounting for 946 trials, followed by the central nervous system with 686 trials and cardiovascular trials with 258. Therefore, the rising number of clinical trials is driving the growth of generative AI in the drug discovery market.

Major companies operating in the generative AI in the drug discovery market are developing advanced AI-powered tools to accelerate drug discovery processes. AI-powered tools streamline drug development by supporting drug discovery, design, and clinical trials through predictive analytics and machine learning. These technologies improve efficiency in areas such as target identification and compound screening, including AI-based virtual screening, preclinical development, regulatory compliance, and manufacturing processes. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, introduced two innovative AI-driven solutions, the Target and Lead Identification Suite and the Multiomics Suite, to advance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite helps researchers understand amino acid functions and predict protein structures, while the Multiomics Suite accelerates genomic data analysis and interpretation, simplifying the development of personalized treatments.

In May 2023, Recursion Pharmaceuticals, a US-based clinical-stage TechBio company, acquired Cyclica and Valence for $40 million and $47.5 million, respectively. Through these acquisitions, Recursion significantly strengthened its drug discovery capabilities by incorporating advanced technologies. The transactions further position Recursion as a hub for leading professionals in machine learning (ML) and artificial intelligence (AI), supporting continued innovation and advancement in drug discovery. Cyclica Inc. is a Canada-based biotechnology company specializing in data-driven drug discovery, biophysics, and artificial intelligence for developing predictive analytics software, while Valence Labs is a Canada-based AI-driven research organization focused on advancing AI applications in drug discovery.

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc.

North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generative artificial intelligence (AI) in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generative AI in drug discovery market includes revenues earned by entities by providing services such as molecule generation, optimization, virtual screening, predictive modeling, de novo drug design, and consulting support. The market value includes the value of related goods sold by the service provider or included within the service offering. The generative AI in drug discovery market also includes sales of quantum computers, high-performance computing (HPC) clusters, tensor processing units, graphics processing units, and preclinical development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

This product will be delivered within 3-5 business days.